Liang Huoyan, Ding Xianfei, Li Hongyi, Li Lifeng, Sun Tongwen
General ICU, First Affiliated Hospital of Zhengzhou University, Henan Key Laboratory of Critical Care Medicine, Zhengzhou, China.
Cancer Centre, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Front Pharmacol. 2020 May 19;11:738. doi: 10.3389/fphar.2020.00738. eCollection 2020.
Recent studies have shown that prior antiplatelet drug use could ameliorate the risk and mortality of acute respiratory distress syndrome (ARDS). However, the connection between prior acetylsalicylic acid (aspirin) use and the risk of ARDS is unknown. Our primary objective was to perform a meta-analysis on the currently available studies to assess the association between aspirin use prior to ARDS onset and ARDS incidence in at-risk patients.
Two investigators separately searched four research databases: MEDLINE, EMBASE, Cochrane Library, and Web of Science for relevant articles from the earliest available data through to July 14, 2019. In this paper, we performed a meta-analysis of the fixed effects model using the inverse variance-weighted average method to calculate the pooled odds ratios (ORs) and 95% confidence intervals (CIs). The primary outcome was risk of ARDS, and the secondary outcome was the hospital mortality of at-risk patients.
This article included seven studies altogether, enrolling 6,764 at-risk patients. Our meta-analysis revealed that, compared to non-aspirin use, prior aspirin use was linked with a significantly lower incidence of ARDS in at-risk patients (OR, 0.78; 95% CI, 0.64-0.96; = 0.018) with low statistical heterogeneity ( = 1.7%). Additionally, difference between prior aspirin use and non-aspirin use was not remarkable for hospital mortality in at-risk patients (OR, 0.88; 95% CI, 0.73-1.07; = 0.204), and this analysis did not involve statistical heterogeneity ( = 0%).
This article indicates an association between prior aspirin use and a lower incidence of ARDS in at-risk patients, suggesting that aspirin use could potentially lower the risk of ARDS, and the investigation of such an effect is an interesting area for future clinical studies.
近期研究表明,既往使用抗血小板药物可改善急性呼吸窘迫综合征(ARDS)的风险和死亡率。然而,既往使用乙酰水杨酸(阿司匹林)与ARDS风险之间的联系尚不清楚。我们的主要目的是对现有研究进行荟萃分析,以评估ARDS发病前使用阿司匹林与高危患者ARDS发病率之间的关联。
两名研究者分别检索了四个研究数据库:MEDLINE、EMBASE、Cochrane图书馆和Web of Science,以查找从最早可用数据到2019年7月14日的相关文章。在本文中,我们使用逆方差加权平均法对固定效应模型进行荟萃分析,以计算合并比值比(OR)和95%置信区间(CI)。主要结局是ARDS风险,次要结局是高危患者的医院死亡率。
本文共纳入7项研究,涉及6764例高危患者。我们的荟萃分析显示,与未使用阿司匹林相比,既往使用阿司匹林与高危患者ARDS发病率显著降低相关(OR,0.78;95%CI,0.64 - 0.96;P = 0.018),统计异质性较低(I² = 1.7%)。此外,既往使用阿司匹林与未使用阿司匹林在高危患者医院死亡率方面的差异不显著(OR,0.88;95%CI,0.73 - 1.07;P = 0.204),且该分析未涉及统计异质性(I² = 0%)。
本文表明既往使用阿司匹林与高危患者ARDS发病率较低之间存在关联,提示使用阿司匹林可能会降低ARDS风险,对这种效应的研究是未来临床研究的一个有趣领域。